Q2 results, INR 7 dividend and proposed 1:1 bonus issue

Results RestatedResults View source PDF Explain this filing

LALPATHLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹1545.00

prior close

₹1538.50

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.6%+2.2% vs market

Healthcare Service Provider peers, median of 22sector+0.0%+1.6% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Smallcap 250 and 1.6 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.9

15m

+2.4

30m

+4.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.6-0.6+2.2+0.0+1.6

Next day

+5.1+0.1+5.0+0.0+5.1

+2.4-0.5+3.0+0.0+2.4

+0.8-2.0+2.8-2.3+3.1

+0.3-2.2+2.5-3.0+3.3

-0.2-2.3+2.0-0.4+0.2

-0.2-1.7+1.5-0.2+0.1

15d

+0.9-4.6+5.5-1.6+2.6

-1.0-3.7+2.7-5.8+4.8

-4.0-4.2+0.2-7.2+3.2

-7.8-10.9+3.2-14.2+6.4

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Service Provider peers, median of 22Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 and H1 FY2025-26 results were approved; the auditor reported no material misstatement. Standalone revenue rose 12.9% to INR 2,750 million in Q2; H1 revenue edged up to INR 6,407 million. The board declared a second interim dividend of INR 7 per share, record date November 7, and proposed a 1:1 bonus issue of about 83.78 million shares. The bonus needs shareholder approval. Standalone results were restated after the Suburban Diagnostics liquidation.

Likely market impact

The dividend and bonus may lift investor interest, but revenue growth was modest. The bonus adds no value and raises share count; approval is pending.